Patients with medication-refractory OAB symptoms should be further treated with neuromodulation - Wikidata - awgldk - TriplyDB

Patients with medication-refractory OAB symptoms should be further treated with neuromodulation

Patients with medication-refractory OAB symptoms should be further treated with neuromodulation

http://www.wikidata.org/entity/Q35137862

about

Chiropractic management of pubic symphysis shear dysfunction in a patient with overactive bladder.Overactive bladder, differential diagnosis, and clinical utility of fesoterodine Purinergic inhibitory regulation of murine detrusor muscles mediated by PDGFRα+ interstitial cells.

P2860

Q35064775-8EFFCA43-5105-4ABE-8B69-3EB07472C767 Q36429651-68C2A3E3-7E8D-42D1-87B8-A96733A774CD Q44212098-EE0BF036-3D09-4CFE-B9BA-195C173AE4F2

P2860

Patients with medication-refractory OAB symptoms should be further treated with neuromodulation

http://www.wikidata.org/entity/Q35137862

description

2011 nî lūn-bûn

@nan

2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Patients with medication-refra ...... r treated with neuromodulation

@ast

Patients with medication-refra ...... r treated with neuromodulation

@en

type

label

Patients with medication-refra ...... r treated with neuromodulation

@ast

Patients with medication-refra ...... r treated with neuromodulation

@en

prefLabel

Patients with medication-refra ...... r treated with neuromodulation

@ast

Patients with medication-refra ...... r treated with neuromodulation

@en

P1433

Q35137862-D89C9F8C-11FC-48E7-828B-094E114BC711

P1476

Q35137862-5420E5FB-2976-496C-9ED3-A79C96FB575B

P2093

Q35137862-D6F3F1A7-6A3C-4268-B5B4-8B821396D82C

P2860

Q35137862-1A5522F4-ED5D-4B6A-8302-946C806EB5F5

Q35137862-254C8CC0-700D-490B-A9E8-6C52FBB393C0

Q35137862-42E08905-82C9-40FA-9B93-C21EB5BDFA6E

Q35137862-5A2FC36B-EEB7-435E-A79B-7CC5D0387BE7

Q35137862-6E9EF56E-9D2B-4EA7-8882-8F474EB8FDEB

Q35137862-7AEC3B20-BF4A-43D2-AB3D-755021B534B4

Q35137862-8787EC0D-7E54-411B-9240-04CE6EC802C4

Q35137862-9032231B-EA0E-4818-88C4-DC71CBDBFAC4

Q35137862-B4CB7ADB-12D5-4FEC-A4E0-F0F0FF5919B4

Q35137862-B62DEC74-5515-4C89-82CD-A282844FFC32

P304

Q35137862-AA8093C9-0719-488E-93F5-DA05667BD661

P31

Q35137862-8C4AF995-D5D5-431F-BCB2-49F1060A9264

P356

Q35137862-C4375B0F-8395-431D-BF63-0DB030CC4D7E

P433

Q35137862-BA77C891-BBD3-4B63-9CA2-AE085336DFD1

P478

Q35137862-E407DBDC-BA8C-46F1-B07A-09667B6B696D

P577

Q35137862-8D2C4B95-1E26-4EAF-807B-973A90BB1D66

P5875

Q35137862-8807B696-8E3D-4B6A-AA7D-5240CDF75A74

P698

Q35137862-933CCFFB-419C-4294-ABF9-6EE4EA1141C4

P932

Q35137862-2B81B54D-39C5-400E-AD61-8C0F936B0A0D

P356

P1433

Canadian Urological Association journal = Journal de l'Association des urologues du Canada

P1476

Patients with medication-refra ...... r treated with neuromodulation

@en

P2093

Jerzy B Gajewski

http://www.w3.org/2001/XMLSchema#string

P2860

Prevalence, management and impact of urinary incontinence in the workplace.

Prevalence and burden of overactive bladder in the United States.

Efficacy and safety of sacral nerve stimulation for urinary urge incontinence: a systematic review.

Refractory idiopathic urge urinary incontinence and botulinum A injection.

A review of adherence to drug therapy in patients with overactive bladder.

Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder.

Satisfaction and patient experience with sacral neuromodulation: results of a single center sample survey.

Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin A treatment for patients with idiopathic overactive bladder.

Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial.

Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study.

P304

283-284

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5489/CUAJ.11039

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2011-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51532988

http://www.w3.org/2001/XMLSchema#string

P698

21801688

http://www.w3.org/2001/XMLSchema#string

P932

3147045

http://www.w3.org/2001/XMLSchema#string